Filing summary
Entity discrepancy: The supplied filing is Synta Pharmaceuticals Corp.’s Form 10-Q, not a Madrigal Pharmaceuticals, Inc. filing. It covers the quarter and six months ended June 30, 2016; financial statements are unaudited.
Business context and reporting period
Synta had no marketed products or product revenue and had historically focused on oncology drug development. After terminating its Phase 3 GALAXY-2 ganetespib trial for futility, Synta substantially reduced its workforce and discontinued much of its R&D. It reported 10 employees remaining after the February 2016 restructuring and was pursuing a merger with Madrigal.
Key financial metrics
| Metric | Q2 2016 / June 30, 2016 | Comparable period / prior balance |
|---|---|---|
| Revenue | $0 | $0 in Q2 2015 |
| Net loss | $3.4 million for Q2; $9.9 million for first half | $19.8 million for Q2 2015; $40.5 million for first half 2015 |
| Operating expenses | $3.5 million Q2; $9.9 million first half | $19.5 million Q2 2015; $39.8 million first half 2015 |
| Cash from operations | $(19.3) million for first half | $(36.5) million for first half 2015 |
| Cash, cash equivalents and marketable securities | $43.0 million | $66.6 million at December 31, 2015 |
| Working capital | $41.5 million | $68.0 million at June 30, 2015 |
| Total liabilities / debt | $3.4 million total liabilities; term loans essentially repaid | $17.8 million liabilities at December 31, 2015 |
No meaningful revenue margin was reported because there was no revenue. Cash and marketable securities declined by $23.6 million from year-end. The company reported total assets of $44.9 million and stockholders’ equity of $41.6 million at quarter-end.
Material changes versus prior periods
- First-half R&D expense fell 90% to $3.3 million from $32.6 million, primarily reflecting GALAXY-2 termination and workforce reductions. Q2 R&D was reported as a $0.1 million credit, including a $0.9 million reduction in accrued contract research costs.
- First-half G&A expense declined 10% to $6.6 million from $7.3 million; Q2 G&A rose 16% year over year to $3.6 million, partly because of a prior-year stock-compensation reversal.
- First-half net loss improved to $9.9 million from $40.5 million, while cash used in operations improved to $19.3 million from $36.5 million.
- Synta paid the final GECC loan principal and exit fee in June; the remaining $10,000 Oxford loan principal was paid July 1, 2016. No term-loan obligations remained after that payment.
Outlook, merger, and risks
Synta expected its approximately $43.0 million of cash, cash equivalents and marketable securities, together with reduced spending, to fund operations for at least 12 months, assuming no new financing or partnership proceeds. It did not expect to raise funds before the proposed merger. If the merger failed, Synta warned it might need significant additional funding, which might not be available on acceptable terms or at all.
The proposed merger, announced April 13, 2016, was expected to close in Q3 2016, subject to customary conditions, Synta stockholder approval and a minimum net cash condition of $28.5 million. Synta was to issue approximately 253.9 million shares; former Synta holders were expected to own approximately 36% and former Madrigal holders approximately 64% of the combined company. The intended focus was cardiovascular-metabolic disease and NASH, including Madrigal’s Phase 2-ready MGL-3196. Ganetespib activity was limited to support for certain investigator-sponsored ovarian cancer and sarcoma trials; Synta did not plan an immediate IND submission for STA-12-8666.
Other notable risks include dependence on merger completion, no product revenue, uncertain future cash needs and financing availability, and clinical-development uncertainty. Management reported effective disclosure controls and no material legal proceedings or material risk-factor changes from the prior quarter.
Important facts for investors to verify
- Confirm the filing entity: this is Synta’s 10-Q, despite the Madrigal metadata.
- Check whether the merger closed, whether Synta stockholders approved it, and whether the $28.5 million minimum net cash condition was met.
- Review subsequent cash burn, liquidity, and any financing or changes to the stated 12-month runway.
- Verify the status and costs of the remaining ganetespib trials and any further development of Synta’s drug candidates.
- Assess the merger’s share issuance and resulting ownership dilution against the final transaction terms.